Stone Pharmaceutical Group: The approval of the clinical trial of the long-acting octreotide injection in the United States.

Shiyao Group announced in Hong Kong that the long-acting octreotide injection developed by the Group has been approved by the U.S. Food and Drug Administration for clinical trials in the United States. Octreotide is a first-line drug for the treatment of acromegaly and gastrointestinal pancreatic neuroendocrine tumors. Currently, this product has entered the phase III clinical research stage in China.